Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HGG Phase III pediatric high-grade glioma trial
2013-004187-56Phase 3Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Nov 2016
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of valproic acid, temozolomide and chloroquine in glioma, diffuse intrinsic pontine glioma (DIPG), gliomatosis cerebri (GC) and 1 more (3 cohorts), sponsored by Georg-August-Universität Göttingen. Primary endpoint: Event-free survival. Started Nov 2016; status: completed.
02
Drugs
valproic acidtemozolomidechloroquine
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on 2013-004187-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004187-56.